근시 및 노안용 점안약 시장 : 세계 예측(2026-2032년)

The Myopia And Presbyopia Eye Drop Market is projected to grow by USD 2.48 billion at a CAGR of 10.49% by 2032.

Myopia and Presbyopia Eye Drops: Executive Overview

Myopia and presbyopia eye drops address two major refractive-vision challenges through distinct therapeutic approaches. Myopia-focused formulations are primarily associated with slowing progression, especially in children, while presbyopia-focused drops aim to improve near vision by temporarily modifying pupil size or accommodative function. The field is shaped by clinical evidence, regulatory requirements, tolerability, adherence, and the need to differentiate pharmacological treatment from corrective lenses, surgery, and behavioral interventions.

From Vision Correction to Earlier, More Personalized Intervention

The landscape is shifting from a predominantly corrective model toward earlier identification, risk stratification, and treatment selection based on age, progression, ocular health, and daily visual demands. Myopia management increasingly emphasizes pediatric monitoring and long-term safety, whereas presbyopia treatment focuses on convenience, duration of effect, and suitability for adults with different ocular conditions. These shifts place greater importance on validated endpoints, sustained follow-up, patient education, and integration with routine eye-care pathways.

Artificial Intelligence Strengthens Screening, Monitoring, and Evidence Generation

Artificial intelligence can support automated image analysis, refractive-risk identification, progression monitoring, and patient-trial recruitment. Its practical value depends on representative datasets, transparent validation, clinician oversight, and compliance with privacy and medical-device requirements. AI may also improve adherence support by identifying missed doses or changes in visual performance, but it does not replace clinical examination, contraindication assessment, or professional judgment when selecting eye-drop therapy.

Regional Insights: Access, Regulation, and Care Pathways Shape Adoption

North America is characterized by advanced eye-care infrastructure, active pediatric myopia-management practices, and strong attention to clinical evidence and product labeling. Europe combines established ophthalmic services with stringent regulatory and health-technology assessment expectations, while the European Union benefits from coordinated standards alongside national reimbursement differences. Asia-Pacific faces a substantial need for myopia control in several densely populated markets and includes sophisticated pharmaceutical systems as well as uneven access. Latin America is influenced by urbanization, specialist availability, and affordability. The Middle East shows expanding private healthcare capacity but variation in reimbursement and clinical access. Africa presents significant unmet need, with adoption constrained in many settings by shortages of eye-care professionals, diagnostic equipment, and reliable medicine distribution.

Group Insights: Economic and Regulatory Blocs Have Different Priorities

ASEAN markets differ substantially in regulatory maturity, specialist capacity, and affordability, making local registration and distribution partnerships important. BRICS countries combine large and diverse patient populations with varied healthcare financing and domestic manufacturing capabilities, but access remains uneven. The European Union emphasizes evidence, safety, and coordinated regulatory principles while retaining national differences in reimbursement. G7 settings generally have strong diagnostic infrastructure and demanding evidence expectations, with attention to patient-reported outcomes and real-world safety. GCC countries often benefit from concentrated healthcare investment and urban specialist networks, although imported-product dependence can matter. NATO members span diverse health systems, so shared security relationships do not imply uniform ophthalmic policy, access, or procurement.

Country Insights: Diverse Patient Needs Require Localized Strategies

Australia and Canada combine developed eye-care systems with geographically dispersed populations, making primary-care coordination and tele-ophthalmology relevant. Brazil and Mexico must balance specialist access, affordability, and regional disparities. China and India face considerable pediatric myopia-management needs alongside marked differences between urban and rural care. Japan and South Korea have advanced clinical infrastructure and aging populations, supporting interest in both myopia control and presbyopia solutions. France, Germany, Italy, Spain, and the United Kingdom require navigation of established regulatory, clinical, and reimbursement processes, with national variation in access. Russia's healthcare environment and supply conditions require careful assessment of regulatory and distribution constraints. In the United States, specialist-led care, private coverage variation, and strong expectations for clinical documentation influence treatment uptake.

Priorities for Leaders: Prove Safety, Simplify Use, and Build Access

Industry leaders should prioritize well-designed comparative studies with clinically meaningful visual and progression outcomes, clearly separated by indication and age group. Product development should address dosing simplicity, ocular comfort, preservative exposure, storage, and compatibility with contact lenses or other treatments where appropriate. Commercial planning should segment pediatric caregivers, presbyopic adults, optometrists, ophthalmologists, and primary-care referrers rather than treating patients as a single audience. Regional execution should use local regulatory expertise, affordability planning, pharmacovigilance systems, and professional education. Responsible AI deployment should include bias testing, explainability, cybersecurity, and defined clinician accountability.

Research Methodology: Evidence-Led Assessment of Clinical and Market Context

This executive summary uses a structured assessment of the myopia and presbyopia eye-drop field, emphasizing peer-reviewed clinical evidence, regulatory principles, ophthalmic practice patterns, demographic and epidemiological context, and healthcare-access conditions. Findings are organized across the specified regions, country groups, and countries to identify common drivers and meaningful differences. Interpretation distinguishes established clinical considerations from emerging applications, avoids unsupported quantitative claims, and treats AI as an enabling technology whose value depends on validation, governance, and integration with professional care.

Conclusion: Clinical Credibility and Equitable Delivery Will Define Progress

The field is moving toward targeted pharmacological options that complement, rather than eliminate, established vision-correction pathways. Success will depend on demonstrating durable benefit and acceptable safety, maintaining adherence over time, and ensuring that clinicians can identify appropriate patients and monitor response. Regional variation in regulation, reimbursement, specialist capacity, and affordability makes localized implementation essential. Leaders that combine rigorous evidence, patient-centered product design, responsible digital tools, and equitable access planning will be best positioned to advance care for myopia and presbyopia.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Myopia And Presbyopia Eye Drop Market, by Type

• 7.1. Introduction
• 7.2. Myopia
• 7.3. Presbyopia

8. Myopia And Presbyopia Eye Drop Market, by Formulation

• 8.1. Introduction
• 8.2. Liquid Dosage
  • 8.2.1. Solution
  • 8.2.2. Suspension
• 8.3. Semi Solid Dosage
  • 8.3.1. Gel
  • 8.3.2. Ointment

9. Myopia And Presbyopia Eye Drop Market, by Age Group

• 9.1. Introduction
• 9.2. Adults
• 9.3. Geriatrics
• 9.4. Pediatrics

10. Myopia And Presbyopia Eye Drop Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Myopia And Presbyopia Eye Drop Market, by Region

• 11.1. Introduction
• 11.2. Asia-Pacific
• 11.3. North America
• 11.4. Latin America
• 11.5. Europe
• 11.6. Middle East
• 11.7. Africa

12. Myopia And Presbyopia Eye Drop Market, by Group

• 12.1. Introduction
• 12.2. ASEAN
• 12.3. GCC
• 12.4. European Union
• 12.5. BRICS
• 12.6. G7
• 12.7. NATO

13. Myopia And Presbyopia Eye Drop Market, by Country

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. United Kingdom
• 13.7. Germany
• 13.8. France
• 13.9. Russia
• 13.10. Italy
• 13.11. Spain
• 13.12. China
• 13.13. India
• 13.14. Japan
• 13.15. Australia
• 13.16. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. Market Concentration Analysis, 2025
  • 14.2.1. Concentration Ratio (CR)
  • 14.2.2. Herfindahl Hirschman Index (HHI)
• 14.3. Recent Developments & Impact Analysis, 2025
• 14.4. Product Portfolio Analysis, 2025
• 14.5. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. AbbVie Inc.
• 15.2. Acucela Inc.
• 15.3. Alcon Inc.
• 15.4. Alkem Laboratories Ltd.
• 15.5. Bausch Health Companies Inc.
• 15.6. Cipla Limited
• 15.7. Entod Pharmaceuticals Pvt. Ltd.
• 15.8. Eyenovia, Inc.
• 15.9. EyePoint Pharmaceuticals, Inc.
• 15.10. Fera Pharmaceuticals Ltd.
• 15.11. Indoco Remedies Ltd.
• 15.12. Intas Pharmaceuticals Ltd.
• 15.13. Jawa Pharmaceuticals (India) Pvt. Ltd.
• 15.14. Johnson & Johnson Services, Inc.
• 15.15. LENZ Therapeutics LLC
• 15.16. Lupin Limited
• 15.17. Novartis AG
• 15.18. Ocumension Therapeutics Inc.
• 15.19. Ocuphire Pharma Inc.
• 15.20. Orasis Pharmaceuticals Inc.
• 15.21. OSRX Pharmaceuticals LLC
• 15.22. Regeneron Pharmaceuticals, Inc.
• 15.23. Santen Pharmaceutical Co., Ltd.
• 15.24. Sun Pharma Laboratories Ltd.
• 15.25. Sydnexis Inc.
• 15.26. Takeda Pharmaceutical Company Limited
• 15.27. Torrent Pharmaceuticals Ltd.
• 15.28. Visus Therapeutics, Inc.
• 15.29. Vyluma Inc.
• 15.30. Zhaoke Ophthalmology Co., Ltd.

16. Key Experts